Information  X 
Enter a valid email address

Sensyne Health PLC (SENS)

  Print      Mail a friend

Friday 05 February, 2021

Sensyne Health PLC

Management appointments

RNS Number : 0831O
Sensyne Health PLC
05 February 2021
 

Sensyne Health continues to strengthen its management team with two further senior appointments

 

Oxford, U.K. 5 February 2021 : Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, announces that it has appointed Hina Zaman as Managing Director of its Healthcare Division and Martin Gouldstone as Chief Business Officer of its Life Sciences Division.

Hina Zaman joins Sensyne from Babylon Health, where as Product Director she led the company's global product for value-based care and previously its global product proposition in the women's health space. Prior to that, Hina founded the UK's first virtual care platform for women's health, pioneering a new model of personalised, proactive care for health consumers. Hina has extensive experience as a healthcare management consultant, leading change initiatives across the NHS commissioning and provider landscape while at Finnamore Ltd. (now part of GE Healthcare), and in US healthcare systems while at Deloitte . At Sensyne, Hina will lead the Company's focus on the commercialisation of its clinical AI software for remote patient monitoring and decision-making support.

 

Martin Gouldstone is a 30-year life-sciences veteran in business development and corporate finance with deep experience in sourcing and closing major strategic collaborations in both the digital health and pharmaceutical industries. He joins Sensyne on 01 March from Syneos where he was Global SVP Capital Solutions at Syneos One and has held senior positions at BenevolentAI, as Chief Business Officer, BDO as Head of Life Sciences in the UK, Results Healthcare, as a partner and co-lead of its healthcare practice and Quintiles where Martin led M&A in Europe. As CBO of Life Sciences at Sensyne, Martin will be responsible for expanding and growing Sensyne's pharmaceutical industry partnerships, focused both on organic growth and new strategic M&A opportunities that build shareholder value.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

"I'm delighted to welcome Hina and Martin to Sensyne.  They bring deep experience and strong personal networks that further strengthen Sensyne's excellent leadership team and increase our capacity to manage the significant growth we expect to deliver over the coming years." 

-ENDS-

 

 

For more information please contact:

Sensyne Health ( www.sensynehealth.com )

+44 (0) 330 058 1845

Lord (Paul) Drayson PhD FREng FMedSci, Chief Executive Officer

 

Michael Norris, Interim Chief Financial Officer

 

Dr Richard Pye, Chief Investment Officer

 


Consilium Strategic Communications

+44 (0) 7780 600290

Mary-Jane Elliott

 

Sukaina Virji


CSC [email protected]


 

About Sensyne Health www.sensynehealth.com  

 

Sensyne Health plc is a clinical AI company that works in partnership with the NHS and other health systems to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUSSKRAKUURAR

a d v e r t i s e m e n t